Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06858319 · ClinicalTrials.gov registry record · Phase 3
Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.
A Phase 3 study of Kidney Diseases and Glomerular Disease, sponsored by Novartis Pharmaceuticals.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 220
- Enrollment target
- 6
- Study locations
NCT06858319 is a Phase 3 study of Kidney Diseases and Glomerular Disease that is actively recruiting participants, run by Novartis Pharmaceuticals. The registered enrollment target is 220 participants, below the 1,780-participant average among 38 other Kidney Diseases trials with a reported enrollment target (88% lower). The trial reports 6 study locations across 6 states.
The verdict
NCT06858319, a Phase 3 study of Kidney Diseases and Glomerular Disease, is actively recruiting participants, sponsored by Novartis Pharmaceuticals.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 220 participants
- Enrollment target
- 6
- Study locations
Study Summary
The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.
Conditions Studied
Interventions
- DRUG zigakibart
Study Locations (6)
Colorado
- Colorado Kidney Care Nephrology - Denver
New York
- NY Nephrology - Clifton Park
Tennessee
- Knoxville Kidney Center Pllc - Brentwood
Buenos Aires F.D.
- Novartis Investigative Site - Buenos Aires
Other
- Novartis Investigative Site - Santa Fe
Korea
- Novartis Investigative Site - Seoul
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 220 participants |
| Start Date | 2025-07-28 |
| Est. Completion | 2031-06-25 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06858319
The ClinicalTrials.gov registry entry for NCT06858319 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 220 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,780-participant average among 38 other Kidney Diseases trials with a reported enrollment target (88% lower). The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Kidney Diseases appearing as the primary indexed condition, and to 1 intervention - of which zigakibart is the first listed.
NCT06858319 reports 6 study locations spanning 6 distinct geographic areas - top geographies include Colorado, New York, Tennessee.
Frequently Asked Questions
What is clinical trial NCT06858319 about?
NCT06858319 is a clinical study titled "Open-label Extension Study of Zigakibart in Adults With IgA Nephropathy.". The purpose of this study is to determine if zigakibart is safe and effective for long-term use in patients with immunoglobulin A nephropathy (IgAN). This is an extension study for patients who have already completed an another zigakibart study.
What is the current status of trial NCT06858319?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 220 participants. The study started on 2025-07-28. Estimated completion is 2031-06-25.
What conditions does trial NCT06858319 study?
This clinical trial studies the following conditions: Kidney Diseases, Glomerular Disease, Kidney Diseases, Chronic, Glomerulonephritis, IGA, Glomerulopathy.
What interventions are being tested in trial NCT06858319?
The interventions under investigation include: zigakibart (DRUG).
Who is sponsoring clinical trial NCT06858319?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06858319 being conducted?
This trial has 6 study locations across Colorado, New York, Tennessee, Buenos Aires F.D., Korea. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Kidney Transplant Preemptive Therapy or Prophylaxis for CMV Prevention in D+R Recipients
RECRUITING · Phase 3
-
Savolitinib vs. Sunitinib in MET-driven PRCC.
ACTIVE NOT RECRUITING · Phase 3
-
Long Term Extension Study in Patients With Primary Hyperoxaluria
ACTIVE NOT RECRUITING · Phase 3
-
Study of MB-102 (Relmapirazin) and the Use of the MediBeacon® Transdermal GFR Measurement System Using the TGFR Reusable Sensor With Disposable Adhesive Ring
COMPLETED · Phase 3
-
Collaborative Learning to Achieve Refined Interventions for Emory: Kidney Disease
RECRUITING · NA
-
Rutgers University Study of the Genetics of Kidney Disease
RECRUITING
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.